As we reached the end of 2025, we happily share our investment activities once more. This includes promising new portfolio additions, several growth financings and achieved milestones for our portfolio companies.

€24 million investment for Eindhoven-Based ShanX

The medical technology company ShanX Medtech from Eindhoven has raised €24 million for a test designed to determine whether bacteria are resistant to antibiotics. The new method is expected to deliver results within one hour, whereas traditional tests often take several days to produce an outcome. Read the article here and get our further perspective on the ShanX Medtech portfolio page.

As we reached the midpoint of 2025, we happily share our investment activities once more. This includes three new portfolio additions, several growth financings and strategic team hires. For further detail access the document here.

Plasmacure 

The Nijmegen-based woundcare company received €16m investment in a round led by US-based distributor Venture Medical, OostNL, VGZ, Triade and Noaber was highlighted in Het Financieele Dagblad. The article a.o. demonstrates Plasmacure’s technological principle, future path for growth and what sets Plasoma apart as highlighted by Peter Haasjes:

“Its portability and suitability for home use.” In addition, the device operates using regular air, without the need for added noble gases. “That’s a competitive advantage — and Venture Medical recognizes it as such as well.”

Read the full article here.

€22 Million Investment for Utrecht-Based Innovation in Heart Surgery

Could bypass surgery one day be performed without sawing open the breastbone? The Utrecht-based company AMT Medical is bringing that vision closer to reality. With a new €22 million investment, the company is accelerating the development and commercialization of its innovative technology — which uses a laser and a small clip instead of traditional sutures.

This method could enable minimally invasive heart bypass procedures through a small keyhole-sized incision between the ribs, potentially leading to significantly faster recovery times for patients.

We’re proud to have invested in AMT Medical back in 2017, supporting their mission from the early days. The recent funding round includes backing from healthcare entrepreneur Johan Bender, Invest-NL, Oost NL and the European Innovation Council next to current shareholders. The company is now preparing for CE certification in Europe and clinical trials in the U.S., potentially in partnership with the Mayo Clinic.

Interested to learn more? Read the full article here.

NXG in the FD: ‘Why medical startups run out of money’

The Financieele Dagblad highlights the funding challenges for Dutch medical startups that inhibits the startups to realize their potential. This requires us, as Peter Haasjes puts it in the article, to look for follow-up financing before we invest into a startup.

We note a mindset shift from gathering clinical data to later-stage market access and reimbursement, effectively resulting in increased interest for companies with revenue in the United States. The key reasons for this are:

1. The introduction of the MDR which makes obtaining a CE-mark for medical devices more difficult as the process is lengthy and less transparent compared to the FDA.
2. The differences in national reimbursement systems within the European Union.
3. The M&A landscape shift towards primarily acquiring revenue generating companies.

Despite the challenges, we see great potential as Europe has tremendous academic ecosystem that drives advancements in regenerative medicine, minimally invasive surgical technologies, and AI. These innovations promise to transform healthcare by extending life and improving efficiency.

Still, success requires a clear understanding of the reimbursement landscape, a strong ‘go-to-market’ strategy and solid plans for funding through sales or fundraising. We’re excited to engage with companies that align with this vision and discuss strategies to bring these technologies to life.

One thing is sure, the article drives engagement. Read the full article here.

Attendi

Back in 2023, through our second fund, we invested in Attendi, an innovative company that decreases the administrative burden for healthcare professionals. This allows tem to relocate their valuable time to client care. EenVandaag showcased the benefits of the solution on national television, displaying a day-to-day use. View the fragment below.

AMT Medical

Back in 2017, through our first fund, we invested in AMT Medical, a pioneering company creating an innovative heart bypass system technology to decrease the number of open heart surgeries.
Het Financieele Dagblad wrote an interesting article zooming in, amongst others, on the development path of the company, the challenges the company is solving and potential for acquisition. Read the full article here.

Momo Medical

Our recent co-investment with PGGM , UNETI Ventures, Center for Aging + Brain Health Innovation and others got listed in Het Financieele Dagblad. The article a.o. demonstrates Momo Medical’s unique capability to provide safety and save time in nursing homes by providing smart sensors that are placed under mattresses. The full article shows more details such as the 4.5 hour time saving per 90 nursing home inhabitants generated next to an illustration of its quick growth to adoption in 250 nursing homes. Read the full article here.